This article appears in the following Journal of Antimicrobial Chemotherapy issue: Tigecycline, a therapeutic option from a new antimicrobial class (the glycylcyclines) in an era of increasing resistance [View the issue table of contents]
Articles |
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae
1 Clinic of Endoscopic Surgery, Military Medical Academy, 3, Georgi Sofiiski Str, 1606 Sofia, Bulgaria 2 Institute of Antimicrobial Chemotherapy of Smolensk State Medical Academy, 28 Krupskaya Str, 214019 Smolensk, Smolensk Regional Hospital, 27 Prospekt, Gagarina, 214018 Smolensk, Russia 3 Clinical County Hospital Cluj-Napoca Str, Cliniclor nr. 3-5 Cluj-Napoca, Romania 4 Hospital Clinico San Carlos, 28040 Madrid, Spain 5 North Estonia Regional Hospital, Mustamae Centre, Sutiste tee 19, Tallinn 13419, Estonia 6 Wyeth Research, Collegeville, PA, USA 7 Wyeth Research, Paris, France
* Corresponding author. Tel: +1-484-865-8818; Fax: +1-484-865-9262; E-mail: babinct{at}wyeth.com
Objectives: To evaluate the efficacy and safety of tigecycline in patients with selected serious infections caused by resistant Gram-negative bacteria, or failures who had received prior antimicrobial therapy or were unable to tolerate other appropriate antimicrobials. Secondary objectives included an evaluation of the microbiological efficacy of tigecycline and in vitro activity of tigecycline for resistant Gram-negative bacteria.
Methods: This open-label, Phase 3, non-comparative, multicentre study assessed the efficacy and safety of intravenous tigecycline (100 mg initially, then 50 mg 12 hourly for 7–28 days) in hospitalized patients with serious infections including complicated intra-abdominal infection; complicated skin and skin structure infection (cSSSI); community-acquired pneumonia (CAP); hospital-acquired pneumonia, including ventilator-associated pneumonia; or bacteraemia, including catheter-related bacteraemia. All patients had infections due to resistant Gram-negative organisms, including extended-spectrum β-lactamase-producing strains, or had failed on prior therapy or could not receive (allergy or intolerance) one or more agents from three classes of commonly used antibiotics. The primary efficacy endpoint was clinical response in the microbiologically evaluable (ME) population at test of cure (TOC). Safety data included vital signs, laboratory tests and adverse events (AEs).
Results: In the ME population at TOC, the clinical cure rate was 72.2% [95% confidence interval (CI): 54.8–85.8], and the microbiological eradication rate was 66.7% (95% CI: 13.7–78.8). The most commonly isolated resistant Gram-negative pathogens were Acinetobacter baumannii (47%), Escherichia coli (25%), Klebsiella pneumoniae (16.7%) and Enterobacter spp. (11.0%); the most commonly diagnosed serious infection was cSSSI (67%). The most common treatment-emergent AEs were nausea (29.5%), diarrhoea (16%) and vomiting (16%), which were mild or moderate in severity.
Conclusions: In this non-comparative study, tigecycline appeared safe and efficacious in patients with difficult-to-treat serious infections caused by resistant Gram-negative organisms.
Keywords: tetracyclines , multidrug resistance , clinical trials
Present address: e2g Biopharmaceutical Consulting, 994 Skelp Level Road, Downingtown, PA 19335, USA
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. G. Zhanel, P. J. Baudry, F. Tailor, L. Cox, D. J. Hoban, and J. A. Karlowsky Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum {beta}-lactamases, AmpC {beta}-lactamases and reduced susceptibility to carbapenems using an in vitro model J. Antimicrob. Chemother., October 1, 2009; 64(4): 824 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Nicasio, J. L. Crandon, and D. P. Nicolau In Vivo Pharmacodynamic Profile of Tigecycline against Phenotypically Diverse Escherichia coli and Klebsiella pneumoniae Isolates Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2756 - 2761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Koomanachai, A. Kim, and D. P. Nicolau Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model J. Antimicrob. Chemother., May 1, 2009; 63(5): 982 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Gordon and D. W. Wareham A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline J. Antimicrob. Chemother., April 1, 2009; 63(4): 775 - 780. [Abstract] [Full Text] [PDF]
|
|